🇺🇸 FDA
Patent

US 10420851

Stabilized radiolabeled anti-CD45 immunoglobulin compositions

granted A61KA61K2035/124A61K2039/505

Quick answer

US patent 10420851 (Stabilized radiolabeled anti-CD45 immunoglobulin compositions) held by Actinium Phamaceuticals, Inc. expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Actinium Phamaceuticals, Inc.
Grant date
Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2035/124, A61K2039/505, A61K35/28, A61K39/39591